<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Hepatol Commun</journal-id><journal-id journal-id-type="iso-abbrev">Hepatol Commun</journal-id><journal-id journal-id-type="pmc-domain-id">3345</journal-id><journal-id journal-id-type="pmc-domain">hep</journal-id><journal-id journal-id-type="publisher-id">HC9</journal-id><journal-title-group><journal-title>Hepatology Communications</journal-title></journal-title-group><issn pub-type="epub">2471-254X</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11781763</article-id><article-id pub-id-type="pmcid-ver">PMC11781763.1</article-id><article-id pub-id-type="pmcaid">11781763</article-id><article-id pub-id-type="pmcaiid">11781763</article-id><article-id pub-id-type="pmid">39878651</article-id><article-id pub-id-type="doi">10.1097/HC9.0000000000000634</article-id><article-id pub-id-type="publisher-id">HEP4-24-0849</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="Version of Record" vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Short-term costs of alcohol-associated hepatitis care in different clinical settings</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Nguyen</surname><given-names initials="CM">Chi Mai</given-names></name><xref rid="aff1" ref-type="aff">1</xref><email>cmnguyen@iu.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="J">Jing</given-names></name><xref rid="aff1" ref-type="aff">1</xref><email>su1@iu.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yang</given-names></name><xref rid="aff1" ref-type="aff">1</xref><email>yli18@iu.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Healey</surname><given-names initials="R">Ryan</given-names></name><xref rid="aff1" ref-type="aff">1</xref><email>ryhealey@iu.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="S">Shihui</given-names></name><xref rid="aff1" ref-type="aff">1</xref><email>sarjiang@iu.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="J">Jiangqiong</given-names></name><xref rid="aff1" ref-type="aff">1</xref><email>jli6@iu.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chalasani</surname><given-names initials="N">Naga</given-names></name><xref rid="aff2" ref-type="aff">2</xref><email>nchalasa@iu.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gawrieh</surname><given-names initials="S">Samer</given-names></name><xref rid="aff2" ref-type="aff">2</xref><email>sgawrieh@iu.edu</email></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6504-8123</contrib-id><name name-style="western"><surname>Liangpunsakul</surname><given-names initials="S">Suthat</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><email>sliangpu@iu.edu</email></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tu</surname><given-names initials="W">Wanzhu</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff4" ref-type="aff">4</xref><email>wtu1@iu.edu</email></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Biostatistics &amp; Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA</aff><aff id="aff2"><label>2</label>Department of Medicine, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA</aff><aff id="aff3"><label>3</label>Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA</aff><aff id="aff4"><label>4</label>Regenstrief Institute Inc., Indianapolis, Indiana, USA</aff><author-notes><corresp><bold>Correspondence</bold> Suthat Liangpunsakul, Department of Medicine, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, 702 Rotary Circle, Indianapolis, IN 46202, USA. Email: <email>sliangpu@iu.edu</email>Wanzhu Tu, Department of Biostatistics &amp; Health Data, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Email: <email>wtu1@iu.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>29</day><month>1</month><year>2025</year></pub-date><volume>9</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">479741</issue-id><elocation-id>e0634</elocation-id><history><date date-type="received"><day>5</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>9</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>30</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-03 19:25:15.270"><day>03</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0</ext-link> (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>
</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="hc9-9-e0634.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hc9-9-e0634.pdf"/><abstract><sec><title>Background:</title><p>Alcohol-associated hepatitis (AH) leads to high rates of mortality and health care costs. Understanding the immediate costs after an AH diagnosis and identifying key cost factors is crucial for health care policies and clinical decisions.</p></sec><sec><title>Objectives:</title><p>This study quantifies medical costs within 30 days of an AH diagnosis across outpatient (OP), emergency department (ED), and inpatient (IP) settings. It also explores concurrent diagnoses and their effects on care costs.</p></sec><sec><title>Methods:</title><p>We conducted a retrospective cohort study using deidentified data from Optum&#8217;s Clinformatics Data Mart. The cohort included individuals aged 21 years and older diagnosed with AH from January 1, 2016, to September 30, 2023. Patients were categorized by care setting (OP, ED, or IP). Costs were calculated for the 30 days before and after AH diagnosis and adjusted to 2023-dollar values. Comorbidities were identified using Elixhauser comorbidity software, and multivariable linear regression models were used to analyze medical costs.</p></sec><sec><title>Results:</title><p>The cohort included 34,974 individuals diagnosed with AH: 8048 in OP (23%), 2736 in ED (7.8%), and 24,190 in IP (69.2%). Average spending in the 30 days prior to AH diagnosis was $7334 for OP, $5740 for ED, and $14,458 for IP. Following AH diagnosis, average costs rose to $8345 for OP, $20,990 for ED, and $88,655 for IP, reflecting increases of 14%, 266%, and 413%, respectively. Significant cost drivers in IP included comorbidities associated with moderate-to-severe liver disease, metabolic syndrome, liver transplant, and mortality during the 30-day follow-up period.</p></sec><sec><title>Conclusions:</title><p>Immediate costs following an AH diagnosis are substantial, particularly for IP care. Costs increase significantly with high-cost comorbidity clusters and among patients who die, underscoring the need for effective management of comorbidities in AH care.</p></sec></abstract><kwd-group><title>Keywords:</title><kwd>alcohol-associated hepatitis</kwd><kwd>cost</kwd><kwd>clinical settings</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta><custom-meta><meta-name>Read-along</meta-name><meta-value>YES</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Alcohol-associated hepatitis (AH) is the most severe form of alcohol-associated liver disease (ALD), characterized by significant morbidity, mortality, and financial repercussions.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref><xref rid="R2" ref-type="bibr"><sup>2</sup></xref><xref rid="R3" ref-type="bibr"><sup>3</sup></xref> Historically, the prognosis for severe AH has been poor, largely due to the lack of effective treatments.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref><xref rid="R5" ref-type="bibr"><sup>5</sup></xref> Abstinence from alcohol is critical for stabilizing the disease,<xref rid="R6" ref-type="bibr"><sup>6</sup></xref><xref rid="R7" ref-type="bibr"><sup>7</sup></xref> and management typically involves a comprehensive approach, including interventions for alcohol use disorder (AUD), such as counseling, behavioral therapies, and pharmacological treatments.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> For severe AH with liver failure, liver transplantation may be considered for eligible patients. However, the limited availability of transplantable organs and stringent eligibility criteria present substantial challenges, making transplantation unattainable for many individuals with severe AH.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref><xref rid="R9" ref-type="bibr"><sup>9</sup></xref><xref rid="R10" ref-type="bibr"><sup>10</sup></xref>
</p><p>There has been a notable increase in the rates of AH-related hospitalization and readmission.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref><xref rid="R12" ref-type="bibr"><sup>12</sup></xref> This trend has significantly strained health care resources and elevated costs for patients, insurers, and care facilities.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref><xref rid="R13" ref-type="bibr"><sup>13</sup></xref><xref rid="R14" ref-type="bibr"><sup>14</sup></xref><xref rid="R15" ref-type="bibr"><sup>15</sup></xref> Despite this, there is limited understanding of the immediate financial impact of AH, including cost differences across various care settings and the factors contributing to the elevated costs. While existing studies have explored the long-term costs of managing AH,<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> the short-term costs following AH diagnosis have been largely unexplored. Understanding these short-term costs is crucial for assessing the economic impact of AH, as not all long-term costs can be directly attributed to the disease. Gaining insight into acute care costs associated with AH could inform health care policy, enhance clinical decision-making, and improve resource allocation within health care systems.</p><p>In this study, we analyzed data from a national claims database to evaluate medical costs within 30 days of an AH diagnosis across outpatient (OP), emergency department (ED), and inpatient (IP) settings. We also examined concurrent diagnoses to assess their impact on care costs in these settings.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study design and data source</title><p>We conducted a retrospective cohort study using deidentified data from Optum&#8217;s Clinformatics Data Mart (CDM), provided by Indiana University (IU). The CDM contains claims data for ~75 million individuals across all 50 US states, covering both commercially insured and Medicare Advantage populations. This database offers comprehensive information on demographics, medical diagnoses, procedures, and services across OP, ED, and IP, along with associated charges for the duration of each individual&#8217;s enrollment. A key advantage of the Optum data is its relative completeness regarding medical charges and mortality information. The IU Human Research Protection Program reviewed this study and deemed it Institutional Review Board exempt, thereby not requiring a full Institutional Review Board review.</p></sec><sec sec-type="cases"><title>Case identification and cohort derivation</title><p>The study cohort included individuals aged 21 and older who received their first AH diagnosis as recorded in the CDM database between January 1, 2016, and September 30, 2023. Patients with AH were identified using the International Classification of Diseases, Tenth Revision (ICD-10) code K70.1, which is used for both OP and IP services and is required for reimbursement by the Centers for Medicare and Medicaid Services.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> To ensure the accuracy of AH identification, we applied a validation strategy similar to that developed by Swain et al<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> and conducted additional sensitivity analyses by verifying the presence of AUD diagnoses (eg, alcohol misuse, dependence, and withdrawal) and AH-related complications, including cirrhosis (with and without ascites), gastrointestinal (GI) bleeding, hepatorenal syndrome or renal failure, and HE.</p><p>To focus on health care costs directly attributable to AH, we applied several exclusion criteria: patients who had received palliative care at least seven days prior to their AH diagnosis, had fewer than 30 days of continuous insurance coverage before their AH diagnosis, or had missing medical records within 30 days of diagnosis were excluded from the analysis. All patients meeting these criteria were followed for 30 days, including those who died during this period. To capture immediate costs associated with AH care, we selected a 30-day follow-up period. Given the typical 1- to 2-week course of acute AH,<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> we used a narrower classification window, spanning 7 days before to 7 days after the AH diagnosis, to categorize patients into three distinct groups based on their care settings: OP, ED care (received care in the ED within 7&#160;d of AH diagnosis without hospitalization), and IP care (hospital admission within 7&#160;d of AH diagnosis).</p></sec><sec><title>Cost calculation</title><p>Costs were calculated for both the pre-AH and post-AH periods across care settings. These costs encompassed all charges for medical, professional, and auxiliary services during the study period, including acute and nonacute medical services, laboratory tests, procedures, visits, and drug or therapeutic expenses. Detailed information on the specific categories of services included in the cost calculations is provided in Supplemental Table S1, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/HC9/B871" ext-link-type="uri">http://links.lww.com/HC9/B871</ext-link>. To allow for a fair comparison, costs were prorated to a 30-day period when the observation period was shortened by patient death. All costs were adjusted to 2023-dollar values using the monthly Consumer Price Index for Medical Care, published by the US Bureau of Labor Statistics.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> This adjustment standardizes costs across different years, ensuring they are comparable throughout the study period.</p></sec><sec><title>Comorbid conditions</title><p>Comorbidities are expected to impact medical costs significantly.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> To account for all concurrent comorbidities present at the time of AH diagnosis, we included all available diagnoses recorded within seven days of the diagnosis. We used the Elixhauser Comorbidity Software Refined for ICD-10-CM, developed by the Healthcare Cost and Utilization Project with support from the Agency for Healthcare Research and Quality.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><xref rid="R22" ref-type="bibr"><sup>22</sup></xref> Comorbidities were coded as binary indicators to assess their presence or absence. Additional details on the sources of comorbidity identification can be found in Supplemental Table S2, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/HC9/B871" ext-link-type="uri">http://links.lww.com/HC9/B871</ext-link>.</p></sec><sec><title>Statistical analysis</title><p>The baseline characteristics of cohort participants were summarized according to care settings: OP, ED, and IP. Continuous variables were described using means and SD, while categorical variables were presented as frequencies (n) and percentages (%). ANOVA was used to compare means of continuous variables, while chi-squared tests or Fisher exact tests were employed for categorical variables. Comorbidities likely to occur concurrently were clustered using the Ward hierarchical agglomerative clustering method based on the Pearson correlation coefficient.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><xref rid="R24" ref-type="bibr"><sup>24</sup></xref> The optimal number of clusters was determined using the average Silhouette score, which quantifies the similarity of an object to members within its cluster compared to other clusters.<xref rid="R25" ref-type="bibr"><sup>25</sup></xref> The prevalence rates of the identified comorbidity clusters were then reported for each care setting.</p><p>In analyzing cost data, values less than $1 were rounded to $1 before applying a natural logarithm transformation, a common method for normalizing skewed data distributions. Point estimates of mean costs and associated CIs were calculated using logarithmically transformed data and then converted back to the original dollar scale. Multivariable linear regression models assessed the associations between comorbidity clusters and 30-day post-AH medical costs (transformed to the logarithmic scale) within each care setting to identify drivers of elevated costs. The analysis considered baseline characteristics (sex, race, age at AH diagnosis, pre-AH medical spending, liver transplant history, year of AH diagnosis), comorbidity status, subsequent liver transplant, and mortality within 30 days of diagnosis. For the IP cohort, the length of hospital stay was also included due to its potential impact on post-AH costs.</p><p>Sensitivity analyses were conducted to evaluate the robustness of the findings. Following established strategies for validating AH and alcohol-associated cirrhosis,<xref rid="R17" ref-type="bibr"><sup>17</sup></xref><xref rid="R26" ref-type="bibr"><sup>26</sup></xref><xref rid="R27" ref-type="bibr"><sup>27</sup></xref> we identified individuals with and without diagnoses of AUD and various forms of liver decompensation. We then excluded individuals from the IP cohort who did not have concurrent diagnoses of AUD and liver decompensation to re-evaluate their post-AH costs. All statistical analyses were performed using R version 4.1.2, with <italic toggle="yes">p-</italic>values &lt;0.05 considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Baseline characteristics of the study cohort</title><p>The derivation of the study cohort is illustrated in Figure <xref rid="F1" ref-type="fig">1</xref>. Table <xref rid="T1" ref-type="table">1</xref> presents the characteristics of the study participants at the time of AH diagnosis. The full study cohort comprised 8048 participants in the OP subgroup (23.0%), 2736 in the ED subgroup (7.8%), and 24,190 in the IP subgroup (69.2%). Women represented approximately one-third of each subgroup (OP: 31.0%; ED: 34.1%; IP: 33.4%). Most participants were white, with the highest proportion in the IP subgroup (OP: 69.6%; ED: 67.2%; IP: 71.7%). The mean ages were 57.5 &#177; 13.4 years in the OP subgroup, 51.6 &#177; 14.5 years in the ED subgroup, and 55.6 &#177; 13.8 years in the IP subgroup. Patients younger than 50 years were more prevalent in the ED subgroup (45.2%) compared to the IP (32.9%) and OP (28.1%) subgroups. Conversely, patients aged 65 and older were more common in the OP subgroup (35.6%) than in the IP (30.1%) and ED (22.5%) subgroups. Approximately 35% of participants in the OP subgroup had no medical costs within a month before the AH diagnosis, compared to 52.0% in the ED subgroup and 50.7% in the IP subgroup.</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Derivation of the study cohort. Abbreviations: AH, alcohol-associated hepatitis; ED, emergency department; IP, inpatient.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="hc9-9-e0634-g001.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Patient characteristics and comorbidity at the time of alcohol-associated hepatitis (AH) diagnosis</p></caption><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Variable</th><th align="center" colspan="1" rowspan="1">OP</th><th align="center" colspan="1" rowspan="1">ED</th><th align="center" colspan="1" rowspan="1">IP</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Women, n (%)</td><td align="center" colspan="1" rowspan="1">2496 (31)</td><td align="center" colspan="1" rowspan="1">932 (34.1)</td><td align="center" colspan="1" rowspan="1">8081 (33.4)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Men, n (%)</td><td align="center" colspan="1" rowspan="1">5552 (69)</td><td align="center" colspan="1" rowspan="1">1804 (65.9)</td><td align="center" colspan="1" rowspan="1">16,109 (66.6)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Race, n (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;White</td><td align="center" colspan="1" rowspan="1">5605 (69.6)</td><td align="center" colspan="1" rowspan="1">1839 (67.2)</td><td align="center" colspan="1" rowspan="1">17,338 (71.7)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;African</td><td align="center" colspan="1" rowspan="1">762 (9.5)</td><td align="center" colspan="1" rowspan="1">306 (11.2)</td><td align="center" colspan="1" rowspan="1">2409 (9.96)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hispanic</td><td align="center" colspan="1" rowspan="1">765 (9.5)</td><td align="center" colspan="1" rowspan="1">250 (9.1)</td><td align="center" colspan="1" rowspan="1">1767 (7.3)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Asian</td><td align="center" colspan="1" rowspan="1">207 (2.57)</td><td align="center" colspan="1" rowspan="1">35 (1.28)</td><td align="center" colspan="1" rowspan="1">341 (1.41)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="center" colspan="1" rowspan="1">709 (8.81)</td><td align="center" colspan="1" rowspan="1">306 (11.18)</td><td align="center" colspan="1" rowspan="1">2335 (9.65)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Age at AH diagnosis (mean, SD)</td><td align="center" colspan="1" rowspan="1">57.5 (13.4)</td><td align="center" colspan="1" rowspan="1">51.6 (14.5)</td><td align="center" colspan="1" rowspan="1">55.6 (13.8)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="5" rowspan="1">Age group, n (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;[1] Age&lt;50</td><td align="center" colspan="1" rowspan="1">2264 (28.1)</td><td align="center" colspan="1" rowspan="1">1238 (45.2)</td><td align="center" colspan="1" rowspan="1">7969 (32.9)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;[2] 50-lt65</td><td align="center" colspan="1" rowspan="1">2917 (36.2)</td><td align="center" colspan="1" rowspan="1">882 (32.2)</td><td align="center" colspan="1" rowspan="1">8931 (36.9)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;[3] 65 plus</td><td align="center" colspan="1" rowspan="1">2867 (35.6)</td><td align="center" colspan="1" rowspan="1">616 (22.5)</td><td align="center" colspan="1" rowspan="1">7290 (30.1)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="5" rowspan="1">Any pre-AH medical spending</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes, n (%)</td><td align="center" colspan="1" rowspan="1">5204 (64.7)</td><td align="center" colspan="1" rowspan="1">1312 (48)</td><td align="center" colspan="1" rowspan="1">11,924 (49.3)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Amount if yes (mean, SD)</td><td align="center" colspan="1" rowspan="1">11,342 (30,900)</td><td align="center" colspan="1" rowspan="1">11,970 (30,950)</td><td align="center" colspan="1" rowspan="1">29,331 (100,987)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Pre-AH medical spending (mean, SD)</td><td align="center" colspan="1" rowspan="1">7334 (25,431)</td><td align="center" colspan="1" rowspan="1">5740 (22,247)</td><td align="center" colspan="1" rowspan="1">14,458 (72,401)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Any pre-AH IP/ER encounter</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes, n (%)</td><td align="center" colspan="1" rowspan="1">1028 (12.8)</td><td align="center" colspan="1" rowspan="1">407 (14.9)</td><td align="center" colspan="1" rowspan="1">4521 (18.7)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Any liver transplant history</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes, n (%)</td><td align="center" colspan="1" rowspan="1">36 (0.45)</td><td align="center" colspan="1" rowspan="1">4 (0.15)</td><td align="center" colspan="1" rowspan="1">126 (0.52)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Comorbidity, n (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Chronic blood loss anemia</td><td align="center" colspan="1" rowspan="1">66 (0.82)</td><td align="center" colspan="1" rowspan="1">21 (0.77)</td><td align="center" colspan="1" rowspan="1">921 (3.81)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Peptic ulcer with bleeding</td><td align="center" colspan="1" rowspan="1">75 (0.93)</td><td align="center" colspan="1" rowspan="1">43 (1.57)</td><td align="center" colspan="1" rowspan="1">1169 (4.83)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Weight loss</td><td align="center" colspan="1" rowspan="1">273 (3.39)</td><td align="center" colspan="1" rowspan="1">107 (3.91)</td><td align="center" colspan="1" rowspan="1">4392 (18.2)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Deficiency anemias</td><td align="center" colspan="1" rowspan="1">864 (10.7)</td><td align="center" colspan="1" rowspan="1">285 (10.4)</td><td align="center" colspan="1" rowspan="1">9263 (38.3)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Coagulopathy</td><td align="center" colspan="1" rowspan="1">520 (6.46)</td><td align="center" colspan="1" rowspan="1">333 (12.2)</td><td align="center" colspan="1" rowspan="1">10,542 (43.6)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Liver disease, moderate to severe</td><td align="center" colspan="1" rowspan="1">729 (9.06)</td><td align="center" colspan="1" rowspan="1">244 (8.92)</td><td align="center" colspan="1" rowspan="1">7785 (32.2)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Pulmonary circulation disease</td><td align="center" colspan="1" rowspan="1">44 (0.55)</td><td align="center" colspan="1" rowspan="1">10 (0.37)</td><td align="center" colspan="1" rowspan="1">706 (2.92)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Congestive heart failure (CHF)</td><td align="center" colspan="1" rowspan="1">216 (2.68)</td><td align="center" colspan="1" rowspan="1">105 (3.84)</td><td align="center" colspan="1" rowspan="1">3164 (13.1)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Valvular disease</td><td align="center" colspan="1" rowspan="1">118 (1.47)</td><td align="center" colspan="1" rowspan="1">48 (1.75)</td><td align="center" colspan="1" rowspan="1">2260 (9.34)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Obesity</td><td align="center" colspan="1" rowspan="1">690 (8.57)</td><td align="center" colspan="1" rowspan="1">175 (6.4)</td><td align="center" colspan="1" rowspan="1">3784 (15.6)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Renal failure</td><td align="center" colspan="1" rowspan="1">301 (3.74)</td><td align="center" colspan="1" rowspan="1">101 (3.7)</td><td align="center" colspan="1" rowspan="1">2794 (11.6)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Diabetes</td><td align="center" colspan="1" rowspan="1">1047 (13.0)</td><td align="center" colspan="1" rowspan="1">316 (11.5)</td><td align="center" colspan="1" rowspan="1">4149 (17.2)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hypertension (HTN)</td><td align="center" colspan="1" rowspan="1">2953 (36.7)</td><td align="center" colspan="1" rowspan="1">1226 (44.8)</td><td align="center" colspan="1" rowspan="1">15,182 (62.8)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Chronic pulmonary disease</td><td align="center" colspan="1" rowspan="1">639 (7.94)</td><td align="center" colspan="1" rowspan="1">317 (11.6)</td><td align="center" colspan="1" rowspan="1">5009 (20.7)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Peripheral vascular disease (PVD)</td><td align="center" colspan="1" rowspan="1">345 (4.29)</td><td align="center" colspan="1" rowspan="1">105 (3.84)</td><td align="center" colspan="1" rowspan="1">2111 (8.73)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Cancer</td><td align="center" colspan="1" rowspan="1">338 (4.2)</td><td align="center" colspan="1" rowspan="1">57 (2.1)</td><td align="center" colspan="1" rowspan="1">1192 (4.9)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Psychoses</td><td align="center" colspan="1" rowspan="1">200 (2.49)</td><td align="center" colspan="1" rowspan="1">108 (3.95)</td><td align="center" colspan="1" rowspan="1">1993 (8.2)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Depression</td><td align="center" colspan="1" rowspan="1">689 (8.56)</td><td align="center" colspan="1" rowspan="1">350 (12.8)</td><td align="center" colspan="1" rowspan="1">5877 (24.3)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Drug abuse</td><td align="center" colspan="1" rowspan="1">157 (1.95)</td><td align="center" colspan="1" rowspan="1">128 (4.68)</td><td align="center" colspan="1" rowspan="1">2415 (9.98)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Cerebrovascular disease (CBVD)</td><td align="center" colspan="1" rowspan="1">118 (1.47)</td><td align="center" colspan="1" rowspan="1">44 (1.61)</td><td align="center" colspan="1" rowspan="1">1331 (5.5)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Paralysis</td><td align="center" colspan="1" rowspan="1">29 (0.36)</td><td align="center" colspan="1" rowspan="1">15 (0.55)</td><td align="center" colspan="1" rowspan="1">398 (1.65)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Dementia</td><td align="center" colspan="1" rowspan="1">65 (0.81)</td><td align="center" colspan="1" rowspan="1">48 (1.75)</td><td align="center" colspan="1" rowspan="1">1289 (5.33)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Neurological disorder</td><td align="center" colspan="1" rowspan="1">207 (2.57)</td><td align="center" colspan="1" rowspan="1">222 (8.11)</td><td align="center" colspan="1" rowspan="1">6,694 (27.7)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;AIDS</td><td align="center" colspan="1" rowspan="1">54 (0.7)</td><td align="center" colspan="1" rowspan="1">7 (0.3)</td><td align="center" colspan="1" rowspan="1">154 (0.6)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.031</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Arthropathies</td><td align="center" colspan="1" rowspan="1">144 (1.79)</td><td align="center" colspan="1" rowspan="1">33 (1.21)</td><td align="center" colspan="1" rowspan="1">628 (2.6)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Thyroid disorders</td><td align="center" colspan="1" rowspan="1">573 (7.12)</td><td align="center" colspan="1" rowspan="1">157 (5.74)</td><td align="center" colspan="1" rowspan="1">2532 (10.5)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Total</bold>
</td><td align="center" colspan="1" rowspan="1"><bold>8048</bold>
</td><td align="center" colspan="1" rowspan="1"><bold>2736</bold>
</td><td align="center" colspan="1" rowspan="1"><bold>24,190</bold>
</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Abbreviations: AH, alcohol-associated hepatitis; CBVD, cerebrovascular disease; CHF, congestive heart failure; ED, emergency department; HTN, hypertension; IP, inpatient; OP, outpatient; PVD, peripheral vascular disease.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Comorbidities and their clusters</title><p>Prevalence rates of comorbidities by care setting are detailed in Table <xref rid="T1" ref-type="table">1</xref>. Nearly all comorbidities were more prevalent in the IP subgroup compared to the OP and ED subgroups, with the exceptions of cancer (4.2% in OP, 2.1% in ED, and 4.9% in IP) and HIV/AIDS (0.7% in OP, 0.3% in ED, and 0.6% in IP). In the IP subgroup, the most prevalent comorbidities included hypertension (62.8%), coagulopathy (43.6%), deficiency anemias (38.3%), moderate to severe liver disease (32.2%), neurological disorders (27.7%), and depression (24.3%). Clustering analysis identified 10 clusters of comorbidities that frequently appeared together. Figure <xref rid="F2" ref-type="fig">2</xref>A illustrates the correlation patterns among these comorbidities. For instance, moderate to severe liver disease, coagulopathy, anemia, and weight loss were often correlated. Another cluster comprised obesity, hypertension, diabetes, and chronic kidney disease, primarily representing metabolic syndromes and their related consequences. Similarly, depression, drug abuse, and psychosis frequently co-occurred in the study cohort. The prevalence rates of these clusters are shown in Figure <xref rid="F2" ref-type="fig">2</xref>B, while the prevalence of individual comorbidities within each cluster is detailed in Supplemental Table S3, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/HC9/B871" ext-link-type="uri">http://links.lww.com/HC9/B871</ext-link>. The dendrogram and silhouette plots used to determine the optimal number of clusters are presented in Supplemental Figure S1, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/HC9/B872" ext-link-type="uri">http://links.lww.com/HC9/B872</ext-link>.</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>(A) Clustered comorbidities by correlation; (B) Prevalence of each cluster in 3 care settings. Abbreviations: Anemdef, deficiency anemias; CHF, congestive heart failure; CBVD, cerebrovascular disease; Chronic pulm, chronic pulmonary disease; HTN, hypertension; liver_msev, moderate to severe liver disease; Neuro, neurological disorders; Pulmon circ, pulmonary circulation disease; PVD, peripheral vascular disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="hc9-9-e0634-g002.jpg"/></fig></sec><sec sec-type="subjects"><title>Medical costs in patients with alcohol-associated hepatitis</title><p>The mean medical costs and SDs during the pre-AH period were $7334 &#177; 25,431 for the OP setting, $5740 &#177; 22,246 for the ED, and $14,458 &#177; 72,401 for the IP setting. In the post-AH period, the mean costs were $8345 &#177; 31,776 for OP, $20,990 &#177; 32,854 for ED, and $88,655 &#177; 131,042 for IP. The mean post-AH medical costs and their distributions across each care setting are presented in Figure <xref rid="F3" ref-type="fig">3</xref>. Post-AH care costs varied significantly by care setting, with mean costs for patients in the ED and IP settings being 2.5 and 10.6 times higher, respectively, than those in OP settings. Notably, the 95% CIs for the mean costs shown in Figure <xref rid="F3" ref-type="fig">3</xref>A were relatively narrow due to the large sample size of the study cohort. Figure <xref rid="F3" ref-type="fig">3</xref>B demonstrates that cost distributions were normalized after logarithmic transformation, supporting the use of transformed data for analysis. Among 24,190 IPs, only 232 (&lt;1%) received liver transplantation within 30 days of AH diagnosis. Their mean costs were $39,410 (SD=$105,849) in the pre-AH period and $435,098 (SD=$455,095) in the post-AH period.</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>The 30-day post-AH medical costs in 3 patient care settings. Abbreviations: AH, alcohol-associated hepatitis; ED, emergency department; IP, inpatient; OP, outpatient.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="hc9-9-e0634-g003.jpg"/></fig><p>Concurrent diagnoses of other ALD and complications related to AH, such as alcohol-associated fibrosis and sclerosis, cirrhosis, gastrointestinal bleeding, ascites, hepatic encephalopathy, and alcohol-associated hepatic failure, were associated with significantly increased care costs in hospitalized patients. Table <xref rid="T2" ref-type="table">2</xref> shows differences in post-AH costs for IPs with and without the above conditions. For example, the average post-AH costs for those with gastrointestinal bleeding and cirrhosis were respectively 1.5 and 1.7 times those without these conditions. The costs for those with hepatorenal syndrome or renal failure, HE, and hepatic failure were more than doubled than those without.</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>The 30-day post-AH costs in dollar value of 2023 of hospitalized patients with AH with and without cirrhosis, coagulopathy, and AUD</p></caption><table frame="hsides" rules="groups"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><thead><tr><th align="left" colspan="1" rowspan="1">Diagnosis</th><th align="center" colspan="1" rowspan="1">Inpatients without diagnoses</th><th align="center" colspan="1" rowspan="1">Inpatients with diagnoses</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Coagulopathy</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="char" char="(" colspan="1" rowspan="1">67,936 (91,796)</td><td align="char" char="(" colspan="1" rowspan="1">115,479 (164,986)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="char" char="(" colspan="1" rowspan="1">40,679 (21,313; 78,880)</td><td align="char" char="(" colspan="1" rowspan="1">65,665 (34,144; 132,118)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="4" rowspan="1">Alcohol-associated cirrhosis</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="char" char="(" colspan="1" rowspan="1">70589 (109340)</td><td align="char" char="(" colspan="1" rowspan="1">120432 (157372)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="char" char="(" colspan="1" rowspan="1">40,135 (21,482; 78,009)</td><td align="char" char="(" colspan="1" rowspan="1">73,350 (39,032; 141,228)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="4" rowspan="1">Cirrhosis, other and unspecified</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="char" char="(" colspan="1" rowspan="1">73,040 (109,596)</td><td align="char" char="(" colspan="1" rowspan="1">124,855 (165,114)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="char" char="(" colspan="1" rowspan="1">41,717 (22,283; 81,345)</td><td align="char" char="(" colspan="1" rowspan="1">75,762 (40,179; 147,552)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="4" rowspan="1">GI hemorrhage</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="char" char="(" colspan="1" rowspan="1">76,113 (107,901)</td><td align="char" char="(" colspan="1" rowspan="1">111,719 (162,852)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="char" char="(" colspan="1" rowspan="1">43230 (22435; 86,269)</td><td align="char" char="(" colspan="1" rowspan="1">63646 (33,784; 127,219)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="4" rowspan="1">HRS/renal failure</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="char" char="(" colspan="1" rowspan="1">60,659 (75,451)</td><td align="char" char="(" colspan="1" rowspan="1">146,842 (189,785)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="char" char="(" colspan="1" rowspan="1">39,509 (21,789; 71,946)</td><td align="char" char="(" colspan="1" rowspan="1">91,348 (45,141; 176,904)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="4" rowspan="1">Ascites</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="char" char="(" colspan="1" rowspan="1">70,492 (99,528)</td><td align="char" char="(" colspan="1" rowspan="1">136,552 (182,134)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="char" char="(" colspan="1" rowspan="1">41,543 (22,289; 80,042)</td><td align="char" char="(" colspan="1" rowspan="1">82,704 (43,609; 160,234)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="4" rowspan="1">HE</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="char" char="(" colspan="1" rowspan="1">67,815 (98,584)</td><td align="char" char="(" colspan="1" rowspan="1">146,645 (182,604)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="char" char="(" colspan="1" rowspan="1">41,010 (22,308; 76,895)</td><td align="char" char="(" colspan="1" rowspan="1">91,820 (47,896; 172,655)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="4" rowspan="1">Alcohol-associated hepatic failure</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="char" char="(" colspan="1" rowspan="1">79,480 (114,989)</td><td align="char" char="(" colspan="1" rowspan="1">166,248 (209,414)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="char" char="(" colspan="1" rowspan="1">46,214 (24,145; 89,988)</td><td align="char" char="(" colspan="1" rowspan="1">106,295 (54,372; 199,874)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="4" rowspan="1">Alcohol abuse, dependence, or withdrawal</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="char" char="(" colspan="1" rowspan="1">96,963 (146,015)</td><td align="char" char="(" colspan="1" rowspan="1">87,917 (129,605)</td><td align="char" char="." colspan="1" rowspan="1">0.765</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="char" char="(" colspan="1" rowspan="1">53,798 (22,332; 114047)</td><td align="char" char="(" colspan="1" rowspan="1">49,566 (25,916; 99,655)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="4" rowspan="1">Alcohol-associated fatty liver</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="char" char="(" colspan="1" rowspan="1">88,698 (132,375)</td><td align="char" char="(" colspan="1" rowspan="1">87,939 (106,450)</td><td align="char" char="." colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="char" char="(" colspan="1" rowspan="1">49,512 (25,386; 100,747)</td><td align="char" char="(" colspan="1" rowspan="1">55,172 (29,389; 104,267)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="4" rowspan="1">Alcohol-associated fibrosis and sclerosis</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="char" char="(" colspan="1" rowspan="1">88,329 (129,494)</td><td align="char" char="(" colspan="1" rowspan="1">166,486 (329,102)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="char" char="(" colspan="1" rowspan="1">49,648 (25,610; 100,576)</td><td align="char" char="(" colspan="1" rowspan="1">93,241 (48,753; 193,275)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr><tr><td align="left" colspan="4" rowspan="1">Alcohol-associated liver disease, unspecified</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mean (SD)</td><td align="char" char="(" colspan="1" rowspan="1">86,146 (128,005)</td><td align="char" char="(" colspan="1" rowspan="1">109,186 (152,136)</td><td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Median (IQR)</td><td align="char" char="(" colspan="1" rowspan="1">48,383 (24,870; 97,767)</td><td align="char" char="(" colspan="1" rowspan="1">62,831 (33,524; 127,570)</td><td align="center" colspan="1" rowspan="1">&#8212;</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>
<italic toggle="yes">Note</italic>: <italic toggle="yes">p-</italic>value of nonparametric Wilcoxon rank sum test.</p></fn><fn fn-type="other"><p>Abbreviations: GI, gastrointestinal; HRS, hepatorenal syndrome.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Factors associated with increased post-AH medical cost</title><p>Separate multiple linear regression models were employed to examine the effects of patient characteristics on post-AH care costs across the 3 subgroups. The results of these regression analyses are summarized in Figure <xref rid="F4" ref-type="fig">4</xref>. While the impact of demographic factors on costs varied by care setting, certain comorbidity clusters were generally associated with increased medical expenses.</p><fig position="float" id="F4" orientation="portrait"><label>FIGURE 4</label><caption><p>Factors associated with the post-AH medical costs in the 3 care setting. Abbreviations: AH, alcohol-associated hepatitis; CBVD, clusters of cerebrovascular disease; CHF, congestive heart failure; HTN, hypertension; LD, liver disease&#65279;; LOS, length of stay&#65279;; PVD, peripheral vascular disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="hc9-9-e0634-g004.jpg"/></fig><p>Across all care settings, the cluster comprising coagulopathy, deficiency anemias, moderate-to-severe liver disease, and weight loss was the most significant contributor to higher costs, increasing medical expenses by ~112%, 42%, and 39% (&#946;=0.73, 0.35, and 0.33) in the OP, ED, and IP settings, respectively. Supplemental Table S5, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/HC9/B871" ext-link-type="uri">http://links.lww.com/HC9/B871</ext-link>, lists the top 10 diagnostic codes for each condition within this cluster, with portal hypertension and various forms of hepatic failure being the most common diagnoses for liver disease, particularly in the IP setting. Another influential cluster included congestive heart failure (CHF), valvular diseases, and/or pulmonary circulation disorders, contributing to increases in costs of 52%, 27%, and 31% (&#946;=0.42, 0.24, and 0.27) in the OP, ED, and IP settings, respectively. The cluster of neurological disorders and/or dementia was associated with increases in care costs of 26%, 36%, and 21% (&#946;=0.23, 0.31, and 0.19), while the cluster of chronic pulmonary disease, peripheral vascular disease (PVD), or cancer led to increases of 80%, 22%, and 15% (&#946;=0.59, 0.20, and 0.14) in the OP, ED, and IP settings, respectively. Additionally, although less common, peptic ulcers with bleeding and chronic blood loss anemias were highly associated with increased costs.</p><p>The cluster of hypertension, diabetes, obesity, and renal failure was prevalent across all care settings but did not significantly increase costs in the OP setting; however, it did in the ED and IP settings. Clusters of cerebrovascular disease and/or paralysis, thyroid disorders, and arthropathies significantly impacted costs in the OP and IP settings but not in the ED. Depression, drug abuse, and psychoses were prevalent and significantly influenced costs in the IP group, consistent with previous studies.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref><xref rid="R28" ref-type="bibr"><sup>28</sup></xref><xref rid="R29" ref-type="bibr"><sup>29</sup></xref>
</p><p>Mortality during the 30-day post-AH period was generally rare in the OP setting, with a mortality rate of 0.2%. This rate was slightly higher in the ED subgroup at 0.8%, and it was most pronounced in the IP setting, where the mortality rate reached 5.4%. Patients who died incurred significantly higher costs compared to those who survived across all care settings (Supplemental Table S4, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/HC9/B871" ext-link-type="uri">http://links.lww.com/HC9/B871</ext-link>).</p></sec><sec><title>Sensitivity analysis</title><p>Analysis revealed that 98.3% of patients hospitalized with AH had a concurrent diagnosis of AUD, liver cirrhosis, or an AH-related complication, confirming the high specificity of using ICD code K70.1 for identifying AH. In comparison, 85.9% of patients seen in the ED and 64.3% of those in OP care settings had similar diagnoses. Notably, the prevalence of alcohol abuse, dependence, and withdrawal was highest in the IP group (91.8%), followed by the ED (73.5%) and OP (43.7%) groups. Similarly, we examined the proportions of patients with a concurrent diagnosis of other ALD, including alcohol-associated fatty liver disease, alcohol-associated fibrosis or sclerosis, alcohol-associated cirrhosis, and alcohol-associated hepatic failure, in all three care settings. Summaries are presented in Supplemental Table S6, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/HC9/B871" ext-link-type="uri">http://links.lww.com/HC9/B871</ext-link>.</p><p>
Table <xref rid="T2" ref-type="table">2</xref> presents the medical costs for patients with AH with and without concurrent diagnoses of cirrhosis, coagulopathy, alcohol abuse, dependence, or withdrawal. In a separate sensitivity analysis, we assessed the robustness of the post-AH cost analysis by excluding individuals who had ED or IP visits before their first AH diagnosis. The estimated associations involving demographics, comorbidity clusters, and other clinical features remained consistent, with only minor differences in magnitude (Supplemental Figure S2, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/HC9/B873" ext-link-type="uri">http://links.lww.com/HC9/B873</ext-link>).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>AH presents a significant challenge due to its high mortality and morbidity rates.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><xref rid="R31" ref-type="bibr"><sup>31</sup></xref> The lack of effective treatments leaves many patients with AH facing poor and uncertain prognoses, which exacerbates the immediate financial burden on patients, families, and health care systems. While the long-term costs of managing AH are well-documented,<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> short-term costs are less frequently studied. This study aims to elucidate the economic burdens of AH care across different clinical settings, highlighting factors that influence costs and resulting disparities. Medical claims data provide valuable insights into these financial aspects. The Optum data, which includes individuals covered by commercial insurance and Medicare Advantage plans, represents a substantial portion of the general clinical population in the United States. According to a 2020 census report, 66% of individuals with health insurance were covered by private or employment-based plans, while 18.4% were covered by Medicare (including Medicare Advantage) plans.<xref rid="R32" ref-type="bibr"><sup>32</sup></xref> Thus, the current study cohort reflects a significant segment of the US clinical population.</p><p>Data from this study reveal significant variations in the short-term costs of AH care across different clinical settings. In OPsettings, the average medical cost for the initial 30 days following an AH diagnosis was $8,345. In contrast, patients who visited the ED or received IP care incurred average costs of $20,990 and $88,655, respectively, during the same period. These costs are 2.5 and 10.6 times higher than those in the OP setting, underscoring the substantial economic burden of AH care in ED and IP settings. The IP cost estimate of $88,655 in our study is comparable to the average cost of an AH-related hospital stay of $84,642 reported in a previous study.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> However, this estimate is lower than the 30-day IP costs for congestive heart failure ($147,392; SD=$225,659) and chronic obstructive pulmonary disease ($113,040; SD=$169,215) reported by Optum during the same study period. Nonetheless, the short-term costs following an AH diagnosis are substantial, emphasizing the urgent need for targeted interventions and resource management strategies to mitigate the economic impact of AH while ensuring optimal patient outcomes.</p><p>AH can occur as the first incidence of liver injury or on a background of pre-existing ALD, including alcohol-associated fatty liver, alcohol-associated fibrosis, and alcohol-associated cirrhosis. In the current study cohort, alcohol-associated cirrhosis tended to be highly prevalent, occurring in 19% of OPs, 18% in patients seen at ED, and 36% in hospitalized patients. The condition could reflect pre-existing liver disease or indicate AH progression to cirrhosis. Previous studies have shown that a substantial proportion of patients with AH have underlying cirrhosis,<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> and biopsy-proven cirrhosis was well documented in participants in treatment trials of AH.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref> The current study reaffirms such observations while showing that other AH-related complications, such as ascites, hepatorenal syndrome, and HE, are also common, especially in hospitalized patients.</p><p>The presence of AH-related complications often results in significantly increased short-term medical costs following AH diagnosis. While this finding may not be surprising, it reinforces the notion that costs are driven by the severity of AH. The need for more intensive medical interventions to treat these complications, as well as extended hospital stays, likely contributes to the increased costs. Timely treatment of these complications may help reduce costs and improve patient outcomes. Notably, among patients hospitalized for AH, more than a third had a concurrent diagnosis of liver cirrhosis (alcohol-associated or otherwise), and 35% experienced some form of bleeding in the gastrointestinal tract. Therefore, addressing these issues is essential for improving patient outcomes, as preventing such complications will likely help mitigate the associated care costs.</p><p>The choice of care venue for patients with AH is often determined by the severity of the condition and the individual patient&#8217;s medical needs. Patients receiving care in ED and IP settings are typically more critically ill and vulnerable than those managed on an OP basis. Hospitalization reflects the severity of AH and the patient&#8217;s overall health status, as evidenced by the comorbidity profiles across the three patient groups. Our data indicate that comorbid conditions significantly influence AH care costs. Comorbidities such as coagulopathy, anemia, portal hypertension, and various forms of hepatic failure not only represent complications of AH but also often signal the severity of the underlying condition. Clustering analysis revealed complex relationships among these comorbidities, highlighting the interconnected nature of health conditions that complicate AH management. Several comorbidity clusters emerged as strong correlates of elevated medical costs across all care settings. Notably, clusters involving liver disease, cardiovascular disorders, neurological conditions, and psychiatric issues were consistently associated with increased health care costs.</p><p>The findings of this study have significant implications for clinical practice, health care policy, and resource allocation in the management of AH. Identifying high-cost comorbidity clusters underscores the need for risk stratification and personalized care. Targeted interventions that address prevalent comorbidities, such as cardiovascular conditions, metabolic syndrome, mental health disorders, and substance use disorders, could enhance patient outcomes and reduce overall costs. Additionally, the observed cost differentials across care settings emphasize the importance of improving access to OP services, strengthening community-based support systems, and implementing early preventive measures. These strategies can help mitigate the economic burden of AH while ensuring continuity of care and enhancing patient satisfaction. Investing in addiction treatment services, mental health support, and multidisciplinary care teams could lead to substantial cost savings by reducing disease complications, hospitalizations, and readmissions.</p><p>Several limitations should be considered when interpreting the findings of this study. First, the retrospective nature of the study and reliance on administrative claims data may introduce biases and limitations inherent to such data sources. Additionally, using ICD codes for AH identification may lead to misclassification of AH, as coding practices can vary. However, as demonstrated in the sensitivity analysis, a vast majority of patients had concurrent diagnoses of AUD and AH-related complications, providing reassurance that the individuals included in the current cohort were likely to have AH. Therefore, the cost estimates are likely to be reliable. Nonetheless, the large size of the claims database and the comprehensive nature of the cost categories provide a valuable platform for examining medical costs associated with AH in real-world clinical settings.</p><p>In conclusion, this study offers new insights into the immediate financial burden of AH following diagnosis, highlighting the significant impact of comorbidities on health care costs. By identifying key cost drivers and disparities in care delivery, the study provides valuable information that may inform future policy initiatives and resource allocation strategies aimed at optimizing AH management and improving patient outcomes.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><fig id="s001" position="anchor" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hc9-9-e0634-s001.pdf" position="float" orientation="portrait"/></fig><fig position="float" id="s002" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="hc9-9-e0634-s002.jpg"/></fig><fig position="float" id="s003" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="hc9-9-e0634-s003.jpg"/></fig></sec></body><back><fn-group><fn fn-type="other"><p>Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal&#8217;s website, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.hepcommjournal.com" ext-link-type="uri">www.hepcommjournal.com</ext-link>.</p></fn><fn fn-type="abbr"><p>
<bold>Abbreviations:</bold> AH, Alcohol-associated hepatitis; ALD, alcohol-associated liver disease; AUD, alcohol use disorder; ED, emergency department; ICD, International Classification of Diseases, Tenth Revision; IP, inpatient; OP, outpatient.</p></fn></fn-group><sec><title>AUTHOR CONTRIBUTIONS</title><p>Conceptualization: Wanzhu Tu, Chi Mai Nguyen, Suthat Liangpunsakul, and Jing Su. Data collection and preparation: Chi Mai Nguyen, Jing Su, Ryan Healey, Shihui Jiang, Jiangqiong Li, and Wanzhu Tu. Statistical methodology and data analysis: Chi Mai Nguyen, Yang Li, and Wanzhu Tu. Visualization: Chi Mai Nguyen, Ryan Healey. Data interpretation: Chi Mai Nguyen, Suthat Liangpunsakul, Samer Gawrieh, and Wanzhu Tu. Writing: Wanzhu Tu, Chi Mai Nguyen, Yang Li, and Suthat Liangpunsakul. Critical revision: All authors.</p><sec><title>FUNDING INFORMATION</title><p>This work was supported in part by NIH grants U24 AA026969 (AlcHepNet DCC), U01 AA026917, UH3 AA026903, R01AA030312, Department of Veterans Affairs Merit Award 1I01CX000361, I01 BX006202, and Dean&#8217;s Scholar in Medical Research (to Suthat Liangpunsakul), and 1R21AA031370 (to Suthat Liangpunsakul and Jing Su), and AnalytixIN (Chi Mai Nguyen).</p></sec><sec sec-type="COI-statement"><title>CONFLICTS OF INTEREST</title><p>Samer Gawrieh is a consultant to TransMedics, Pfizer Kowa, Spruce, and Novo Nordisk. He received a research grant from Viking, Sonic Incytes, DSM, and Zydus. Suthat Liangpunsakul discloses consulting roles with Durect Corporation, Surrozen, and Korro Bio. However, these roles do not present any conflict of interest concerning the content of this work. Wanzu Tu received grants from NIH.</p></sec></sec><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jinjuvadia</surname><given-names>R</given-names></name><name name-style="western"><surname>Liangpunsakul</surname><given-names>S</given-names></name></person-group>. <article-title>Trends in alcoholic hepatitis-related hospitalizations, financial burden, and mortality in the United States</article-title>. <source>J Clin Gastroenterol</source>. <year>2015</year>;<volume>49</volume>:<fpage>506</fpage>&#8211;<lpage>511</lpage>.<pub-id pub-id-type="pmid">25198164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCG.0000000000000161</pub-id><pub-id pub-id-type="pmcid">PMC4276725</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marlowe</surname><given-names>N</given-names></name><name name-style="western"><surname>Lam</surname><given-names>D</given-names></name><name name-style="western"><surname>Liangpunsakul</surname><given-names>S</given-names></name></person-group>. <article-title>Epidemic within a pandemic: Alcohol-associated hepatitis and COVID-19</article-title>. <source>Alcohol Clin Exp Res (Hoboken)</source>. <year>2023</year>;<volume>47</volume>:<fpage>1883</fpage>&#8211;<lpage>1889</lpage>.<pub-id pub-id-type="pmid">37553753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acer.15162</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marlowe</surname><given-names>N</given-names></name><name name-style="western"><surname>Lam</surname><given-names>D</given-names></name><name name-style="western"><surname>Krebs</surname><given-names>W</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W</given-names></name><name name-style="western"><surname>Liangpunsakul</surname><given-names>S</given-names></name></person-group>. <article-title>Prevalence, co-morbidities, and in-hospital mortality of patients hospitalized with alcohol-associated hepatitis in the United States from 2015 to 2019</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2022</year>;<volume>46</volume>:<fpage>1472</fpage>&#8211;<lpage>1481</lpage>.<pub-id pub-id-type="pmid">35778777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acer.14896</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thursz</surname><given-names>M</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>TR</given-names></name></person-group>. <article-title>Treatment of severe alcoholic hepatitis</article-title>. <source>Gastroenterology</source>. <year>2016</year>;<volume>150</volume>:<fpage>1823</fpage>&#8211;<lpage>1834</lpage>.<pub-id pub-id-type="pmid">26948886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2016.02.074</pub-id><pub-id pub-id-type="pmcid">PMC5828019</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>E</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>L</given-names></name><name name-style="western"><surname>Parker</surname><given-names>R</given-names></name></person-group>. <article-title>Survival from alcoholic hepatitis has not improved over time</article-title>. <source>PLoS ONE</source>. <year>2018</year>;<volume>13</volume>:<fpage>e0192393</fpage>.<pub-id pub-id-type="pmid">29634763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0195857</pub-id><pub-id pub-id-type="pmcid">PMC5892935</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seitz</surname><given-names>HK</given-names></name><name name-style="western"><surname>Bataller</surname><given-names>R</given-names></name><name name-style="western"><surname>Cortez-Pinto</surname><given-names>H</given-names></name><name name-style="western"><surname>Gao</surname><given-names>B</given-names></name><name name-style="western"><surname>Gual</surname><given-names>A</given-names></name><name name-style="western"><surname>Lackner</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Alcoholic liver disease</article-title>. <source>Nat Rev Dis Primers</source>. <year>2018</year>;<volume>4</volume>:<fpage>16</fpage>.<pub-id pub-id-type="pmid">30115921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-018-0014-7</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Addolorato</surname><given-names>G</given-names></name><name name-style="western"><surname>Mirijello</surname><given-names>A</given-names></name><name name-style="western"><surname>Leggio</surname><given-names>L</given-names></name><name name-style="western"><surname>Ferrulli</surname><given-names>A</given-names></name><name name-style="western"><surname>Landolfi</surname><given-names>R</given-names></name></person-group>. <article-title>Management of alcohol dependence in patients with liver disease</article-title>. <source>CNS Drugs</source>. <year>2013</year>;<volume>27</volume>:<fpage>287</fpage>&#8211;<lpage>299</lpage>.<pub-id pub-id-type="pmid">23456576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40263-013-0043-4</pub-id><pub-id pub-id-type="pmcid">PMC4979989</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>MC</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>LS</given-names></name><name name-style="western"><surname>McClain</surname><given-names>CJ</given-names></name></person-group>. <article-title>Medical management of severe alcoholic hepatitis: Expert review from the clinical practice updates Committee of the AGA Institute</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2017</year>;<volume>15</volume>:<fpage>5</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="pmid">27979049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2016.08.047</pub-id><pub-id pub-id-type="pmcid">PMC5172399</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altamirano</surname><given-names>J</given-names></name><name name-style="western"><surname>L&#243;pez-Pelayo</surname><given-names>H</given-names></name><name name-style="western"><surname>Michelena</surname><given-names>J</given-names></name><name name-style="western"><surname>Jones</surname><given-names>PD</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>L</given-names></name><name name-style="western"><surname>Gin&#232;s</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival</article-title>. <source>Hepatology</source>. <year>2017</year>;<volume>66</volume>:<fpage>1842</fpage>&#8211;<lpage>1853</lpage>.<pub-id pub-id-type="pmid">28646515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.29338</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avance&#241;a</surname><given-names>ALV</given-names></name><name name-style="western"><surname>Miller</surname><given-names>N</given-names></name><name name-style="western"><surname>Uttal</surname><given-names>SE</given-names></name><name name-style="western"><surname>Hutton</surname><given-names>DWH</given-names></name><name name-style="western"><surname>Mellinger</surname><given-names>JL</given-names></name></person-group>. <article-title>Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis</article-title>. <source>J Hepatol</source>. <year>2021</year>;<volume>74</volume>:<fpage>1286</fpage>&#8211;<lpage>1294</lpage>.<pub-id pub-id-type="pmid">33326815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.12.004</pub-id><pub-id pub-id-type="pmcid">PMC8177741</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>TA</given-names></name><name name-style="western"><surname>DeShazo</surname><given-names>JP</given-names></name><name name-style="western"><surname>Thacker</surname><given-names>LR</given-names></name><name name-style="western"><surname>Puri</surname><given-names>P</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group>. <article-title>The worsening profile of alcoholic hepatitis in the United States</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2016</year>;<volume>40</volume>:<fpage>1295</fpage>&#8211;<lpage>1303</lpage>.<pub-id pub-id-type="pmid">27147285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acer.13069</pub-id><pub-id pub-id-type="pmcid">PMC4918810</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peeraphatdit</surname><given-names>TB</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>PS</given-names></name><name name-style="western"><surname>Karpyak</surname><given-names>VM</given-names></name><name name-style="western"><surname>Davis</surname><given-names>B</given-names></name><name name-style="western"><surname>Desai</surname><given-names>V</given-names></name><name name-style="western"><surname>Liangpunsakul</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Alcohol rehabilitation within 30 days of hospital discharge is associated with reduced readmission, relapse, and death in patients with alcoholic hepatitis</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2020</year>;<volume>18</volume>:<fpage>477</fpage>&#8211;<lpage>485.e475</lpage>.<pub-id pub-id-type="pmid">31042580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2019.04.048</pub-id><pub-id pub-id-type="pmcid">PMC9764228</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Martinson</surname><given-names>N</given-names></name><name name-style="western"><surname>Martinson</surname><given-names>M</given-names></name></person-group>. <article-title>Mortality and costs associated with alcoholic hepatitis: A claims analysis of a commercially insured population</article-title>. <source>Alcohol</source>. <year>2018</year>;<volume>71</volume>:<fpage>57</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">30048829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.alcohol.2018.02.003</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Beirne</surname><given-names>J</given-names></name></person-group>. <article-title>Readmission following hospitalization for alcoholic hepatitis: Costly or cost&#8209;effective?</article-title><source>Dig Dis Sci</source>. <year>2020</year>;<volume>65</volume>:<fpage>920</fpage>&#8211;<lpage>921</lpage>.<pub-id pub-id-type="pmid">31571104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-019-05854-6</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liangpunsakul</surname><given-names>S</given-names></name></person-group>. <article-title>Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States</article-title>. <source>J Clin Gastroenterol</source>. <year>2011</year>;<volume>45</volume>:<fpage>714</fpage>&#8211;<lpage>719</lpage>.<pub-id pub-id-type="pmid">21085006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCG.0b013e3181fdef1d</pub-id><pub-id pub-id-type="pmcid">PMC3135756</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vannier</surname><given-names>AG</given-names></name><name name-style="western"><surname>Shay</surname><given-names>JE</given-names></name><name name-style="western"><surname>Fomin</surname><given-names>V</given-names></name><name name-style="western"><surname>Patel</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>E</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>RP</given-names></name><etal/></person-group>. <article-title>Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder</article-title>. <source>JAMA Network Open</source>. <year>2022</year>;<volume>5</volume>:<fpage>e2213014</fpage>.<pub-id pub-id-type="pmid">35594048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.13014</pub-id><pub-id pub-id-type="pmcid">PMC9123494</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swain</surname><given-names>LA</given-names></name><name name-style="western"><surname>Godley</surname><given-names>J</given-names></name><name name-style="western"><surname>Brahmania</surname><given-names>M</given-names></name><name name-style="western"><surname>Abraldes</surname><given-names>JG</given-names></name><name name-style="western"><surname>Tang</surname><given-names>KL</given-names></name><name name-style="western"><surname>Flemming</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Validating new coding algorithms to improve identification of alcohol-associated and nonalcohol-associated cirrhosis hospitalizations in administrative databases</article-title>. <source>Hepatol Commun</source>. <year>2024</year>;<volume>8</volume>:<fpage>e0469</fpage>.<pub-id pub-id-type="pmid">38896072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HC9.0000000000000469</pub-id><pub-id pub-id-type="pmcid">PMC11186834</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="other"><comment>University of Pittsburgh Medical Center. Alcohol and the liver. 2024. Assessed August 5, 2024</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.upmc.com/services/liver-cancer/liver/alcohol-liver" ext-link-type="uri">https://www.upmc.com/services/liver-cancer/liver/alcohol-liver</ext-link></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="book"><collab>Bureau of Labor Statistics</collab>. <source>Consumer Price Index for All Urban Consumers: Medical Care in US City Average</source>, <publisher-loc>U.S</publisher-loc>: <publisher-name>Bureau of Labor Statistics</publisher-name>; <year>2024</year>.</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carstensen</surname><given-names>J</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>D</given-names></name><name name-style="western"><surname>Andr&#233;</surname><given-names>M</given-names></name><name name-style="western"><surname>Engstr&#246;m</surname><given-names>S</given-names></name><name name-style="western"><surname>Magnusson</surname><given-names>H</given-names></name><name name-style="western"><surname>Borgquist</surname><given-names>LA</given-names></name></person-group>. <article-title>How does comorbidity influence healthcare costs? A population-based cross-sectional study of depression, back pain and osteoarthritis</article-title>. <source>BMJ Open</source>. <year>2012</year>;<volume>2</volume>:<fpage>e000809</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2011-000809</pub-id><pub-id pub-id-type="pmcid">PMC3341593</pub-id><pub-id pub-id-type="pmid">22535792</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Healthcare Cost &amp; Utilization Project, AHRQ</collab></person-group>. <comment>Elixhauser Comorbidity Software Refined for ICD-10-CM v2024.1. 2024.</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/comorbidity_icd10.jsp#down" ext-link-type="uri">https://hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/comorbidity_icd10.jsp#down</ext-link></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elixhauser</surname><given-names>A</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>C</given-names></name><name name-style="western"><surname>Harris</surname><given-names>DR</given-names></name><name name-style="western"><surname>Coffey</surname><given-names>RM</given-names></name></person-group>. <article-title>Comorbidity measures for use with administrative data</article-title>. <source>Med Care</source>. <year>1998</year>;<volume>36</volume>:<fpage>8</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">9431328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00005650-199801000-00004</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>JH</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Hierarchical grouping to optimize an objective function</article-title>. <source>J Am Stat Assoc</source>. <year>1963</year>;<volume>58</volume>:<fpage>236</fpage>&#8211;<lpage>244</lpage>.</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murtagh</surname><given-names>F</given-names></name><name name-style="western"><surname>Legendre</surname><given-names>P</given-names></name></person-group>. <article-title>Ward&#8217;s hierarchical agglomerative clustering method: Which algorithms implement Ward&#8217;s criterion?</article-title><source>J Classif</source>. <year>2014</year>;<volume>31</volume>:<fpage>274</fpage>&#8211;<lpage>295</lpage>.</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rousseeuw</surname><given-names>PJ</given-names></name></person-group>. <article-title>Silhouettes: A Graphical Aid to the Interpretation and Validation of Cluster Analysis</article-title>. <source>J Comput Appl Math</source>. <year>1987</year>;<volume>20</volume>:<fpage>53</fpage>&#8211;<lpage>65</lpage>.</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>JX</given-names></name><name name-style="western"><surname>Ross</surname><given-names>E</given-names></name><name name-style="western"><surname>Borman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>GG</given-names></name><name name-style="western"><surname>Heitman</surname><given-names>SJ</given-names></name><etal/></person-group>. <article-title>Risk factors for mortality in patients with alcoholic hepatitis and assessment of prognostic models: A population-based study</article-title>. <source>Can J Gastroenterol Hepatol</source>. <year>2015</year>;<volume>29</volume>:<fpage>131</fpage>&#8211;<lpage>138</lpage>.<pub-id pub-id-type="pmid">25855876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/814827</pub-id><pub-id pub-id-type="pmcid">PMC4399372</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panchal</surname><given-names>SA</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>DE</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>DS</given-names></name><name name-style="western"><surname>Mahmud</surname><given-names>N</given-names></name></person-group>. <article-title>Algorithms to identify alcoholic hepatitis hospitalizations in patients with cirrhosis</article-title>. <source>Dig Dis Sci</source>. <year>2022</year>;<volume>67</volume>:<fpage>4395</fpage>&#8211;<lpage>4402</lpage>; <comment>1-8</comment>.<pub-id pub-id-type="pmid">35022905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-021-07321-7</pub-id><pub-id pub-id-type="pmcid">PMC9276834</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Walraven</surname><given-names>C</given-names></name><name name-style="western"><surname>Austin</surname><given-names>PC</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>A</given-names></name><name name-style="western"><surname>Quan</surname><given-names>H</given-names></name><name name-style="western"><surname>Forster</surname><given-names>AJ</given-names></name></person-group>. <article-title>A modification of the Elixhauser Comorbidity Measures into a point system for hospital death using administrative data</article-title>. <source>Med Care</source>. <year>2009</year>;<volume>47</volume>:<fpage>626</fpage>&#8211;<lpage>633</lpage>.<pub-id pub-id-type="pmid">19433995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MLR.0b013e31819432e5</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharabiani</surname><given-names>M</given-names></name><name name-style="western"><surname>Aylin</surname><given-names>P</given-names></name><name name-style="western"><surname>Bottle</surname><given-names>A</given-names></name></person-group>. <article-title>Systematic review of comorbidity indices for administrative data</article-title>. <source>Med Care</source>. <year>2012</year>;<volume>50</volume>:<fpage>1109</fpage>&#8211;<lpage>1118</lpage>.<pub-id pub-id-type="pmid">22929993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MLR.0b013e31825f64d0</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singal</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kodali</surname><given-names>S</given-names></name><name name-style="western"><surname>Vucovich</surname><given-names>LA</given-names></name><name name-style="western"><surname>Darley-Usmar</surname><given-names>V</given-names></name><name name-style="western"><surname>Schiano</surname><given-names>TD</given-names></name></person-group>. <article-title>Diagnosis and treatment of alcoholic hepatitis: A systematic review</article-title>. <source>Alcohol</source>. <year>2016</year>;<volume>40</volume>:<fpage>1390</fpage>&#8211;<lpage>1402</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acer.13108</pub-id><pub-id pub-id-type="pmcid">PMC4930399</pub-id><pub-id pub-id-type="pmid">27254289</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bataller</surname><given-names>R</given-names></name><name name-style="western"><surname>Arab</surname><given-names>JP</given-names></name><name name-style="western"><surname>Shah</surname><given-names>VH</given-names></name></person-group>. <article-title>Alcohol-associated hepatitis</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2022</year>;<volume>387</volume>:<fpage>2436</fpage>&#8211;<lpage>2448</lpage>.<pub-id pub-id-type="pmid">36577100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra2207599</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Keisler-Starkey</surname><given-names>K</given-names></name><name name-style="western"><surname>Bunch</surname><given-names>LN</given-names></name></person-group>. <source>Health insurance coverage in the United States: 2019</source>. <publisher-name>Census Bureau</publisher-name><source>2020</source>.</mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singal</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>PS</given-names></name><name name-style="western"><surname>Gores</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Shah</surname><given-names>VH</given-names></name></person-group>. <article-title>Alcoholic hepatitis: Current challenges and future directions</article-title>. <source><italic toggle="yes">Clin Gastroenterol Hepatol</italic></source>. <year>2014</year>;<volume>12</volume>:<fpage>555</fpage>&#8211;<lpage>564</lpage>.<pub-id pub-id-type="pmid">23811249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2013.06.013</pub-id><pub-id pub-id-type="pmcid">PMC3883924</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathurin</surname><given-names>P</given-names></name><name name-style="western"><surname>Mendenhall</surname><given-names>CL</given-names></name><name name-style="western"><surname>Carithers</surname><given-names>RL</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Ramond</surname><given-names>M-J</given-names></name><name name-style="western"><surname>Maddrey</surname><given-names>WC</given-names></name><name name-style="western"><surname>Garstide</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): Individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH</article-title>. <source>J Hepatol</source>. <year>2002</year>;<volume>36</volume>:<fpage>480</fpage>&#8211;<lpage>487</lpage>.<pub-id pub-id-type="pmid">11943418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0168-8278(01)00289-6</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>